Brief: Finch Therapeutics Provides Corporate Updates, Reports Q2 Results

Finch Therapeutics

11/08/2022 12:34

Aug 11 (Reuters) - Finch Therapeutics Group Inc  FNCH.O :
    * FINCH THERAPEUTICS PROVIDES CORPORATE UPDATES AND REPORTS
SECOND
QUARTER 2022 FINANCIAL RESULTS
    * FINCH THERAPEUTICS GROUP INC - ON TRACK TO SUBMIT IND FOR
FIN-211 IN CHILDREN WITH AUTISM AND SIGNIFICANT GI SYMPTOMS IN
Q4 2022
    * FINCH THERAPEUTICS GROUP INC - ON TRACK TO PROCEED WITH
ENROLLMENT IN PRISM4 PHASE 3 TRIAL OF CP101 IN RECURRENT CDI IN
H2 2022
    * FINCH THERAPEUTICS GROUP INC - QTRLY LOSS PER SHARE $0.48
    * FINCH THERAPEUTICS GROUP - BELIEVES ITS CASH, EQUIVALENTS
AS OF
JUNE 30, 2022, WILL FUND ITS OPERATIONS INTO Q1 2024
    * FINCH THERAPEUTICS GROUP - TAKEDA INFORMED CO THAT THEY
ARE
CONDUCTING REVIEW OF PLANS, TIMELINE, BUDGET FOR TAK-524 PROGRAM
    * FINCH THERAPEUTICS GROUP - ASSOCIATED NEAR-TERM MILESTONES
HAVE
BEEN REMOVED FROM CO'S CASH RUNWAY ANALYSIS UNTIL TAKEDA HAS
COMPLETED REVIEW

Source text for Eikon:  ID:nGNX3nz1LS 
Further company coverage:  FNCH.O